Chordate Medical Holding (publ) publishes its interim report for Q1 2022 on Friday, May 27th, 2022, at 08:30. On Monday, May 30th at 14:00, the company invites the public to a livestreamed teleconference with CEO Anders Weilandt. The conference is followed by a Q&A session. You can follow the conference via computer or mobile devices.
To register for the web conference, register via the following link: https://attese.gotowebinar.com/register/6856232777036844045
The number of places is limited, so we recommend registering well in advance to secure a place.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.